Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mulholland has 3 groupings of sales listed for December 22nd. One is 12,100 shares all for $7.00. One is 453,997 shares sold for an average of $6.61. One is for 245,704 shares sold for an average of $5.49. In this last grouping, the prices sold for ranges from $5.03 to $5.98. Mulholland starting selling at $7.00 and sold all the way down to $5.03. The stock price bottomed out at $5.00.
https://docoh.com/filing/1257911/0001807094-20-000031/4
2. This transaction was executed in multiple trades at prices ranging from $5.03 to $5.98. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $6.02 to $6.99. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
A Netflex documentary in the making.
No need to waste time on trials
Was this question ever answered?-Name one example in the history of pharmacology where an expensive drug was rejected by the US FDA but then gained significant revenue in 3rd World countries?
Define expensive?
CytoDyn doesn't need approval in the U.S. With billions$$$ revenue coming from countries
CytoDyn is choosing to conduct their trials in poor countries because they said that the SOC is too good now in the US and not enough patients are dying. I have trouble believing that since 47% of placebo criticals passed away and 38% of treatment criticals passed away. But it would indicate that there was far less of a mortality benefit at the end of the trial that there was at the beginning of the trial. We'll never know because they will never release the data.
Maybe he had bills to pay. Maybe pay off his mortgage
How did Molholland time his stock sale so perfectly that he managed to sell at $7.00 the exact peak of the last pump to the exact cent. No one wants to know how he managed to be that lucky? Especially given the fact that he set it up before hand. That's extremely suspicious and I'm surprised this doesn't raise the biggest red flag in recent CYDY history.
GM-CSF is cytokine responsible for the cytokine storm. Lenzilumab is a GM-CSF inhibitor.
https://www.bbc.com/news/health-56352128
https://directorsblog.nih.gov/2021/04/13/mapping-severe-covid-19-in-the-lungs-at-single-cell-resolution/
https://immunology.sciencemag.org/content/6/57/eabg9873
Estrada was on life support in ICU suffering from Covid then given Leronlimab and it saved his life
Leronlimab is not a Lenzilumab or dexamethasone or any other drug witch may produce immunosuppression
Receiving two doses versus 4 will make all the difference
the outrage is left to a few of us on these boards, Twitter and Facebook — those who have done our due diligence, know the science and understand leronlimab’s impact.
More outrage to come. A day of reckoning. They can’t hide it anymore.
Every drug marketed has side effects.
$150MM NET profit
Ultimately, it’s seems you are quite right that LL has to better prove itself to the FDA
flippers
That being said, JW has said that if something is safe and has potential to help (so all these anecdotes? These are potential), that it should be able to be distributed while further tests are run.
I don’t think the share price was at $10 long enough for most to sell but I was able to keep my core under $1 average and take advantage of this roller coaster ride and bank some on multiple occasions
Not everything in this world is a conspiracy. In fact, most things are not. Obviously, there is some corruption in Big Pharma like there is in all capitalist enterprises. Some people will sometimes do the wrong things for money. But the FDA is top notch. There is very little corruption in the FDA, NIH, and CDC. These organizations are made up of very selfless people for the most part. These are people who have dedicated their lives to helping other people. They've spent 12 hours a day on academics since they were in the seventh grade. They could make far more money in the private sector but they choose public service. It is unquestionably disrespectful that they would be attacked and harassed because they didn't give a premature approval to a drug. And the attackers are mostly upset because they want their stock to have a higher price.
When it comes to judging Small Pharma and Big Pharma, Small Pharma is way greasier. Big Pharma does trials. They enroll thousands. They look at the data. If it is bad data, they move on. If it is mediocre data, they move on. Small Pharma cannot do that. CytoDyn only has leronlimab. Covid accounts for the majority of CYDY's market cap. Admitting that leronlimab is a mediocre drug for Covid would cut a billion dollars off of CYDY's market cap.
Adam Feuerstein comes at CYDY because of their greasiness. He understands the pharma sector. He can smell Nader from a mile away. CYDY is most investor's first foray into biotech. It is similar to your first girlfriend/boyfriend. At the time you think they are flawless and you will be together forever. Then you learn better. If nothing else, this investment will be a learning experience for many (too bad you didn't sell at $10.01).
Many CYDY investors agree that Nader is incompetent and dishonest. But they believe in leronlimab the drug. Yet, everything we know about the clinical trials comes from Nader. The M2M trial results are still not available. The CD12 trial results will also never be made public. My guess is that for every bright spot in the data there are 10 warts. But we will never know.
I was without internet until the last hour of trading yesterday, and only looked here a few times using my cell phone.
FDA Acting Head should be getting into her green suit and running for the hills.
It seems that this video has been taken down by whoever posted it. I wonder why since I did not get to see it.
2. Woodcock herself (interim FDA head) said p-values ain't the end all or be all for drugs showing effectiveness. Your 'science' requirement left the building at that moment.
1. Remdesivir gets EUA 'cause it was "trending towards significance" (the quote from our national treasure Fauci).
Explain again why you are so against a very safe and effective drug from getting a chance to help people that need it.
Patients with mild symptoms were being helped by SOC. LL could have been successful if the trial had been limited to ONLY patients with moderate symptoms IMO!
Does it bother anyone that CytoDyn didn't release any topline results from the severe patients in its CD12 trial? Severes make up 331 out of 393 patients in the CD12 trial. And yet, not one tiny bit of topline data has been disclosed about severes.
My guess is that the treatment arm had a higher mortality rate than placebo.
IMO You would want an injection of LL at the very start of the cytokine storm. This could even be done in an out patient setting when breathing issues begin and oxygenation drops below 88%!
Dr Steve Brule has come out in support of leronlimab!
The video is so bad they have already taken it down.
That was pathetic.
https://youtube.com/watch?v=x1NcRlkiSS4&feature=share
Flaming endorsement of CYDY
NOT
Would you still be invested in CYDY if you knew that leronlimab would never get an EUA from the US FDA?
@adamfeuerstein
More misleading, factually incorrect and bizarro statements from the CEO of $CYDY in this video posted today. Again, this is what happens when regulators at the SEC and the FDA are absent, don't care, don't do their job.
Lenzilumab Plus Axi-Cel Achieves Responses in 100% of Patients With DLBCL With Limited Toxicity in Small Study
https://www.targetedonc.com/view/lenzilumab-plus-axi-cel-achieves-responses-in-100-of-patients-with-dlbcl-with-limited-toxicity-in-small-study
Thanks!
if we weren't going up against such strong standard of care
So the only trial in the United States that CytoDyn is going to have is the longhauler trial where they are treating people at a clinic owned by a CytoDyn employee?
Is the FDA going to allow CytoDyn to conduct their 140 patient critical trial in India?